Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer Therapy

U.S. FDA Gives Nod To Bristol-Myers Combo Therapy For Lung Cancer

Posted on May 18, 2020
Post Views: 646

Lung Cancer TherapyNon-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases. Lung cancer patients in advanced stages of the disease have received a new first-line treatment option. The U.S. Food and Drug Administration has approved Bristol Myers Squibb Co’s combination therapy for patients with lung cancer. The use of immunotherapy combination led to improvement in overall survival compared with chemotherapy alone.

The combination of Bristol’s treatments, Opdivo and Yervoy, is approved for treatment of NSCLC patients. This approval support came from positive findings from Part 1 of the phase III CheckMate 227 trial. It explored the nivolumab regimen in comparison with chemotherapy in patients with previously untreated NSCLC. Opdivo spurs the immune system to fight cancer and is one of the Bristol’s top-selling drugs but overtaken by Keytruda as industry’s immunoncology leader.

The study investigator Matthew D. Hellmann, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center said, “Patients with metastatic lung cancer remain in need of new treatment options that may provide durable responses.” “The results from the CheckMate 227 trial show that a dual immunotherapy approach offers a chance at long-term survival for appropriate patients with metastatic NSCLC,” he added.

This FDA approved combination of Opdivo plus Yervoy as a treatment for patients with NSCLC tumors that express programmed death-ligand one (PD-L1) on at least 1% of cells. The combination was specifically approved to treat advanced-stage NSCLC patients with PD-L1 positive tumors that don’t display EDFR mutations or ALK mutations.

“We continue to investigate novel combinations of therapy that may hold the potential to expand the therapeutic benefits of immunotherapy to patients with difficult to treat cancer or those who don’t respond, and look forward to evaluating the combination of Novartis’ MEK inhibitor with our immunotherapies,” said Fouad Namouni. Opdivo is indicated for treatment of NSCLC patients with progression on or after platinum-based chemotherapy.

The information shared in this blog is for educational purposes only.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,325)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,552)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d